A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to evaluate the effect repeated doses of AZD6765 (a drug being developed for the treatment of patients with severe major depressive disorder) has on the PK (pharmacokinetic) profile of Midazolam. (The PK profile is how the drug leaves your body and acts in the body.)

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Midazolam

Criteria

Inclusion Criteria:

• BMI between 19-30

Exclusion Criteria:

• Significant result for C-SSRS at screening or baseline

• Single arm preference for IV procedures